Aerts JGJV - Search Results

1

Tumor mutational load, CD8⁺ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.

Hurkmans DP, Kuipers ME, Smit J, van Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von der Thüsen JH, van der Burg SH. Hurkmans DP, et al. Among authors: aerts jgjv. Cancer Immunol Immunother. 2020 May;69(5):771-777. doi: 10.1007/s00262-020-02506-x. Epub 2020 Feb 12. Cancer Immunol Immunother. 2020. PMID: 32047958 Free PMC article.

2

Dendritic cell-based immunotherapy in mesothelioma.

Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG. Cornelissen R, et al. Immunotherapy. 2012 Oct;4(10):1011-22. doi: 10.2217/imt.12.108. Immunotherapy. 2012. PMID: 23148753 Review.

3

Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP. Heuvers ME, et al. BMC Cancer. 2012 Dec 5;12:580. doi: 10.1186/1471-2407-12-580. BMC Cancer. 2012. PMID: 23217146 Free PMC article. Review.

4

Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.

Aerts JG, Hegmans JP. Aerts JG, et al. Cancer Res. 2013 Apr 15;73(8):2381-8. doi: 10.1158/0008-5472.CAN-12-3932. Epub 2013 Apr 11. Cancer Res. 2013. PMID: 23580578 Review.

5

Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.

Cornelissen R, Lievense LA, Robertus JL, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG. Cornelissen R, et al. Lung Cancer. 2015 Jun;88(3):332-7. doi: 10.1016/j.lungcan.2015.03.013. Epub 2015 Mar 21. Lung Cancer. 2015. PMID: 25843042

6

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH. van Leeuwen RW, et al. J Clin Oncol. 2016 Apr 20;34(12):1309-14. doi: 10.1200/JCO.2015.65.2560. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858332 Clinical Trial.

7

Reply to N. Singh et al.

van Leeuwen RWF, van Gelder T, Aerts JG, Mathijssen RHJ. van Leeuwen RWF, et al. J Clin Oncol. 2016 Nov 20;34(33):4054. doi: 10.1200/JCO.2016.68.9356. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27551130 No abstract available.

8

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.

van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ. van Leeuwen RWF, et al. Clin Pharmacokinet. 2017 Jul;56(7):683-688. doi: 10.1007/s40262-016-0503-3. Clin Pharmacokinet. 2017. PMID: 28101705 Free PMC article.

9

Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.

Steendam CM, Dammeijer F, Aerts JGJV, Cornelissen R. Steendam CM, et al. Among authors: aerts jgjv. Immunotherapy. 2017 May;9(6):507-520. doi: 10.2217/imt-2016-0151. Immunotherapy. 2017. PMID: 28472903 Review.

10

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG. Dammeijer F, et al. Cancer Immunol Res. 2017 Jul;5(7):535-546. doi: 10.1158/2326-6066.CIR-16-0309. Epub 2017 May 23. Cancer Immunol Res. 2017. PMID: 28536100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page